



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Deruxtecan

Cat. No.:	HY-13631E
CAS No.:	1599440-13-7
Molecular Formula:	C ₅₂ H ₅₆ FN ₉ O ₁₃
Molecular Weight:	1034.05
Target:	Drug-Linker Conjugates for ADC
Pathway:	Antibody-drug Conjugate/ADC Related
Storage:	-20°C, protect from light, stored under nitrogen * The compound is unstable in solutions, freshly prepared is recommended.



SOLVENT & SOLUBILITY

In Vitro	DMSO : 35 mg/mL (33.85 mM; Need ultrasonic)					
	Preparing Stock Solutions	Solvent Concentration	Mass	1 mg	5 mg	10 mg
		1 mM		0.9671 mL	4.8354 mL	9.6707 mL
		5 mM		0.1934 mL	0.9671 mL	1.9341 mL
		10 mM		0.0967 mL	0.4835 mL	0.9671 mL
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	<ol style="list-style-type: none"> Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: 1.75 mg/mL (1.69 mM); Suspended solution; Need ultrasonic Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: 1.75 mg/mL (1.69 mM); Suspended solution; Need ultrasonic Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 1.75 mg/mL (1.69 mM); Clear solution 					

BIOLOGICAL ACTIVITY

Description	Deruxtecan is an ADC drug-linker conjugate composed of an DX-8951 derivative (DXd) and amaleimide-GGFG peptide linker, used for synthesizing DS-8201 and U3-1402.
IC₅₀ & Target	Camptothecins
In Vitro	Antibody-drug conjugates deliver anticancer agents selectively and efficiently to tumor tissue and have significant antitumor efficacy with a wide therapeutic window ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- Clin Cancer Res. 2023 Jun 6;CCR-23-0103.
- J Control Release. 2024 Feb 13;367:779-790.
- Mol Cancer Ther. 2023 Sep 5;22(9):1013-1027.
- Biomolecules. 2024 Jan 15, 14(1), 106.
- AAPS J. 2022 May 27;24(4):70.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. NOGUCHI, Shigeru, et al. METHOD FOR SELECTIVELY MANUFACTURING ANTIBODY-DRUG CONJUGATE. WO2017002776A1.

[2]. Ogitani Y, et al. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. Cancer Sci. 2016 Jul;107(7):1039-46.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA